Sensus Healthcare (NASDAQ:SRTS) Shares Cross Above 50-Day Moving Average – Here’s Why

Sensus Healthcare, Inc. (NASDAQ:SRTS)’s stock price passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $3.03 and traded as high as $5.25. Sensus Healthcare shares last traded at $3.29, with a volume of 9,718,144 shares.

Wall Street Analyst Weigh In

Several research analysts recently commented on SRTS shares. Weiss Ratings lowered Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Alliance Global Partners reaffirmed a “buy” rating on shares of Sensus Healthcare in a research note on Monday, August 17th. Finally, Lake Street Capital lowered their price objective on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Sensus Healthcare currently has a consensus rating of “Moderate Buy” and an average price target of $5.83.

Sensus Healthcare Trading Up 19.6%

The stock has a market capitalization of $54.15 million, a PE ratio of -3.50 and a beta of 1.18. The business’s 50 day moving average is $3.03 and its 200 day moving average is $3.53.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%. The firm had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $4.60 million.

Insider Activity

In other Sensus Healthcare news, Director Eric Sachetta bought 37,537 shares of the business’s stock in a transaction dated Friday, August 28th. The shares were purchased at an average price of $3.44 per share, with a total value of $129,127.28. Following the completion of the purchase, the director owned 267,480 shares in the company, valued at $920,131.20. This represents a 16.32% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders purchased a total of 120,171 shares of company stock worth $405,230 in the last ninety days. 10.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Sensus Healthcare

A number of institutional investors and hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp purchased a new position in Sensus Healthcare during the 2nd quarter valued at $303,000. BlackRock Inc. bought a new position in Sensus Healthcare in the 2nd quarter valued at $252,000. Finally, EP Wealth Advisors LLC purchased a new stake in Sensus Healthcare in the second quarter worth $49,000. 25.30% of the stock is owned by institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical device company focused on non-invasive treatment technologies for dermatologic and oncologic conditions. The company develops and commercializes superficial radiotherapy systems designed to deliver low-energy X-rays to targeted areas of the skin.

Its principal products include the SRT-100 and SRT-100 Vision systems, which are used by physicians to treat non-melanoma skin cancers, including basal cell and squamous cell carcinomas, as well as keloids. The systems are intended to provide an alternative to certain surgical procedures and are used in dermatology, radiation oncology and other clinical settings.

Founded in 2010, Sensus Healthcare is headquartered in Boca Raton, Florida.